title: Gene therapy for Parkinson's disease: where are we now and where are we going?
abstract: The number of patients worldwide who have received some kind of gene therapy is now in the thousands. A subset of that number have received intracranial injections of adeno-associated viruses encoding various therapeutic genes directed at ameliorating Parkinson's disease (PD). In this article we briefly examine the current status of Phase I and Phase II trials of gene therapy for PD and preview some of the improvements in delivery technology that promise to make adeno-associated-virus-based gene therapy for PD safer and more accessible to interventional neurologists around the world.
authors.affiliation: Department of Neurological Surgery, University of California-San Francisco, CA 94110-0555, USA.
authors.forename: John
authors.initials: J
authors.lastname: Forsayeth
authors.forename: Krystof S
authors.initials: KS
authors.lastname: Bankiewicz
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Aminoff
mesh_terms: D002986:Clinical Trials as Topic; D000229:Dependovirus / Q000235:genetics; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000235:genetics / Q000628:therapy*